Ernst Chantelau
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Ernst Chantelau has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
- Ludger Wilhelm Poll
Department of Radiology, Berufsgenossenschaftliche Unfallklinik Duisburg GmbH, Großenbaumer Allee 250, 47249 Duisburg/Germany
3 shared publications A. Richter
Diabetes Foot Clinic, Department of Endocrinology, Diabetes and Rheumatology, Heinrich-Heine-University of Düssseldorf, Düsseldorf, Germany
2 shared publicationsL. W. Poll
Department of Diagnostic Radiology, Heinrich-Heine-University of Düssseldorf, Düsseldorf, Germany
2 shared publications- Rolf Meyer-Schwickerath
Augustahospital Anholt, Isselburg-Anholt, Germany
2 shared publications - Ruth Praetor
Cäcilienstr.40, 48431 Rheine, Germany
2 shared publications Tobias Wienemann
Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany
2 shared publications
Latest Publications
- 21 March 2025
- Published by Deutscher Arzte-Verlag GmbH in Deutsches Ärzteblatt international
- Vol. 122 (6) , m1019
Correspondence
- 21 March 2025
- Published by Deutscher Arzte-Verlag GmbH in Deutsches Ärzteblatt international
- Vol. 122 (6) , m1019
Correspondence
- Open Access
- 22 December 2022
- Published by SAGE Publications in Journal of Diabetes Science and Technology
- Vol. 18 (4) , 930-936
Trial of a Trivial Quantitative Heat-Pain Stimulus for Detecting Severe Loss of Nociception
Background: Loss of nociception (LON) at the feet of persons with diabetes mellitus develops gradually over years and remains asymptomatic until the first painless diabetic foot ulceration (DFU). Severe LON with pain insensitivity can be diagnosed with a mechanical (pinprick) pain stimulus of 512-mN force. A comparable “suprathreshold” heat-pain stimulus may have the same potential. Objective: A six-second, 51°C heat-pain stimulus delivered on a 38.5-mm² spot by a commercial medical device ( bite away®, to treat insect bites) was explored in a prospective cross-sectional diagnostic accuracy study to detect DFU-related LON. Methods: Seventy-two participants were studied: 12 with and 30 without diabetic neuropathy according to the conventional criteria, and 30 patients with a history of painless DFU (indicative of end-stage LON, reference standard). The feet were stimulated at the plantar and dorsal sides. A palmar surface was stimulated for control purposes. Participants scored stimulated pain intensity 0 to 10 on a numerical rating scale. Results: At hands, pain intensity was rated six on average by all participants. Persons without neuropathy scored 7 (0-10), median (range), at the plantar side and 8.5 (2-10) at the dorsal side of the foot, while those with DFU scored 0 (0-8) and 0 (0-10), respectively. A pain response of 0 at the foot dorsum detected DFU-related LON with a sensitivity of 65% (specificity, 100%; positive and negative predictive values, 100% and 96%, respectively). Conclusions: Due to its high specificity, the test seems advantageous for diagnostic purposes, complementary to current screening tests.
- 22 December 2022
- Published by SAGE Publications in Journal of Diabetes Science and Technology
- Vol. 18 (4) , 930-936
Open AccessTrial of a Trivial Quantitative Heat-Pain Stimulus for Detecting Severe Loss of Nociception
Background: Loss of nociception (LON) at the feet of persons with diabetes mellitus develops gradually over years and remains asymptomatic until the first painless diabetic foot ulceration (DFU). Severe LON with pain insensitivity can be diagnosed with a mechanical (pinprick) pain stimulus of 512-mN force. A comparable “suprathreshold” heat-pain stimulus may have the same potential. Objective: A six-second, 51°C heat-pain stimulus delivered on a 38.5-mm² spot by a commercial medical device ( bite away®, to treat insect bites) was explored in a prospective cross-sectional diagnostic accuracy study to detect DFU-related LON. Methods: Seventy-two participants were studied: 12 with and 30 without diabetic neuropathy according to the conventional criteria, and 30 patients with a history of painless DFU (indicative of end-stage LON, reference standard). The feet were stimulated at the plantar and dorsal sides. A palmar surface was stimulated for control purposes. Participants scored stimulated pain intensity 0 to 10 on a numerical rating scale. Results: At hands, pain intensity was rated six on average by all participants. Persons without neuropathy scored 7 (0-10), median (range), at the plantar side and 8.5 (2-10) at the dorsal side of the foot, while those with DFU scored 0 (0-8) and 0 (0-10), respectively. A pain response of 0 at the foot dorsum detected DFU-related LON with a sensitivity of 65% (specificity, 100%; positive and negative predictive values, 100% and 96%, respectively). Conclusions: Due to its high specificity, the test seems advantageous for diagnostic purposes, complementary to current screening tests.
- Open Access
- 16 January 2020
- Published by SAGE Publications in Journal of Diabetes Science and Technology
- Vol. 15 (3) , 622-629
A Novel Diagnostic Test for End-Stage Sensory Failure Associated With Diabetic Foot Ulceration: Proof-of-Principle Study
Diabetic foot ulceration (DFU) affects only a subgroup of patients with diabetic neuropathy, that is, those with pain-insensitivity due to end-stage sensory failure. Pain perception failure develops insidiously and remains asymptomatic until first DFU. As loss of pain perception is clinically significant, timely detection is mandatory. A novel suprathreshold pinprick pain stimulus of 512 mN force made from optical glass-fiber was explored in a prospective cross-sectional diagnostic accuracy study to detect DFU-related end-stage sensory failure. A total of 116 participants were studied (25 healthy people, 22 patients with diabetes without relevant complications, 19 patients with previous painful foot or leg injuries, and 50 patients with previous or active painless DFU [reference standard]). Palmar and plantar surfaces were stimulated in a standardized fashion. At the feet, the second and third toe skinfolds and the middle of the plantar arch were stimulated. Participants scored stimulated pricking discomfort or pain intensity 0 to 10 on a numerical rating scale. At hands, intensity was rated on average 5 (1-10) [median (range)] by 114/116 participants. Per foot, participants without DFU scored 5 (1-10), while those with DFU scored 0 (0-3) (P < .0001). At plantar toe skinfolds, the absence of pinprick pain perception detected DFU-associated sensory failure with an accuracy of 99.5% (sensitivity 99.5%, specificity 99.4%, positive likelihood ratio 248, and negative likelihood ratio 0.005). In this pilot study, nociceptive stimulation of a plantar toe skinfold with a 512 mN optical glass-fiber pinprick accurately identified DFU-associated end-stage sensory failure.
- 16 January 2020
- Published by SAGE Publications in Journal of Diabetes Science and Technology
- Vol. 15 (3) , 622-629
Open AccessA Novel Diagnostic Test for End-Stage Sensory Failure Associated With Diabetic Foot Ulceration: Proof-of-Principle Study
Diabetic foot ulceration (DFU) affects only a subgroup of patients with diabetic neuropathy, that is, those with pain-insensitivity due to end-stage sensory failure. Pain perception failure develops insidiously and remains asymptomatic until first DFU. As loss of pain perception is clinically significant, timely detection is mandatory. A novel suprathreshold pinprick pain stimulus of 512 mN force made from optical glass-fiber was explored in a prospective cross-sectional diagnostic accuracy study to detect DFU-related end-stage sensory failure. A total of 116 participants were studied (25 healthy people, 22 patients with diabetes without relevant complications, 19 patients with previous painful foot or leg injuries, and 50 patients with previous or active painless DFU [reference standard]). Palmar and plantar surfaces were stimulated in a standardized fashion. At the feet, the second and third toe skinfolds and the middle of the plantar arch were stimulated. Participants scored stimulated pricking discomfort or pain intensity 0 to 10 on a numerical rating scale. At hands, intensity was rated on average 5 (1-10) [median (range)] by 114/116 participants. Per foot, participants without DFU scored 5 (1-10), while those with DFU scored 0 (0-3) (P < .0001). At plantar toe skinfolds, the absence of pinprick pain perception detected DFU-associated sensory failure with an accuracy of 99.5% (sensitivity 99.5%, specificity 99.4%, positive likelihood ratio 248, and negative likelihood ratio 0.005). In this pilot study, nociceptive stimulation of a plantar toe skinfold with a 512 mN optical glass-fiber pinprick accurately identified DFU-associated end-stage sensory failure.
- Open Access
- 1 January 2018
- Published by Taylor & Francis in Diabetic Foot & Ankle
- Vol. 9 (1) , 1466611
Follow up of MRI bone marrow edema in the treated diabetic Charcot foot – a review of patient charts
Background: Ill-defined areas of water-like signal on bone magnetic resonance imaging (MRI), characterized as bone marrow edema or edema-equivalent signal-changes (EESC), is a hallmark of active-stage pedal neuro-osteoarthropathy (Charcot foot) in painless diabetic neuropathy, and is accompanied by local soft-tissue edema and hyperthermia. The longitudinal effects on EESC of treating the foot in a walking cast were elucidated by reviewing consecutive cases of a diabetic foot clinic. Study design: Retrospective observational study, chart review Material and methods: Cases with active-stage Charcot foot were considered, in whom written reports on baseline and follow-up MRI studies were available for assessment. Only cases without concomitant infection or skin ulcer were chosen, in whom both was documented, onset of symptomatic foot swelling and patient compliance with cast treatment. Results: From 1994 to 2017, 45 consecutive cases in 37 patients were retrieved, with 95 MRI follow-up studies (1–6 per case, average interval between studies 13 weeks). Decreasing EESC was documented in 66/95 (69%) follow-up studies. However, 29/95 (31%) studies revealed temporarily increasing, migrating or stagnating EESC. Conclusion: EESC on MRI disappear in response to prolonged offloading and immobilizing treatment; however, physiologic as well as pathologic fluctuations of posttraumatic EESC have to be considered when interpreting the MR images. Conventional MRI is useful for surveillance of active-stage Charcot foot recovery.
- 1 January 2018
- Published by Taylor & Francis in Diabetic Foot & Ankle
- Vol. 9 (1) , 1466611
Open AccessFollow up of MRI bone marrow edema in the treated diabetic Charcot foot – a review of patient charts
Background: Ill-defined areas of water-like signal on bone magnetic resonance imaging (MRI), characterized as bone marrow edema or edema-equivalent signal-changes (EESC), is a hallmark of active-stage pedal neuro-osteoarthropathy (Charcot foot) in painless diabetic neuropathy, and is accompanied by local soft-tissue edema and hyperthermia. The longitudinal effects on EESC of treating the foot in a walking cast were elucidated by reviewing consecutive cases of a diabetic foot clinic. Study design: Retrospective observational study, chart review Material and methods: Cases with active-stage Charcot foot were considered, in whom written reports on baseline and follow-up MRI studies were available for assessment. Only cases without concomitant infection or skin ulcer were chosen, in whom both was documented, onset of symptomatic foot swelling and patient compliance with cast treatment. Results: From 1994 to 2017, 45 consecutive cases in 37 patients were retrieved, with 95 MRI follow-up studies (1–6 per case, average interval between studies 13 weeks). Decreasing EESC was documented in 66/95 (69%) follow-up studies. However, 29/95 (31%) studies revealed temporarily increasing, migrating or stagnating EESC. Conclusion: EESC on MRI disappear in response to prolonged offloading and immobilizing treatment; however, physiologic as well as pathologic fluctuations of posttraumatic EESC have to be considered when interpreting the MR images. Conventional MRI is useful for surveillance of active-stage Charcot foot recovery.
- 5 June 2017
- Published by Deutscher Arzte-Verlag GmbH in Deutsches Ärzteblatt international
- Vol. 114, 399
Podological Treatment Has a Protective Effect
The results (1) are consistent with earlier reports of amputations in diabetes mellitus. In 2016 May et al. reported a decrease in rates of amputations of the foot in patients insured with a German statutory sickness fund since 2007, and Hagen et al....
- 5 June 2017
- Published by Deutscher Arzte-Verlag GmbH in Deutsches Ärzteblatt international
- Vol. 114, 399
Podological Treatment Has a Protective Effect
The results (1) are consistent with earlier reports of amputations in diabetes mellitus. In 2016 May et al. reported a decrease in rates of amputations of the foot in patients insured with a German statutory sickness fund since 2007, and Hagen et al....
- Open Access
- 1 January 2016
- Published by Taylor & Francis in Diabetic Foot & Ankle
- Vol. 7 (1) , 31922
Conventional deep pressure algometry is not suitable for clinical assessment of nociception in painless diabetic neuropathy
Conventional deep pressure algometry is not suitable for clinical assessment of nociception in painless diabetic neuropathy
- 1 January 2016
- Published by Taylor & Francis in Diabetic Foot & Ankle
- Vol. 7 (1) , 31922
Open AccessConventional deep pressure algometry is not suitable for clinical assessment of nociception in painless diabetic neuropathy
Conventional deep pressure algometry is not suitable for clinical assessment of nociception in painless diabetic neuropathy
- Open Access
- 1 January 2015
- Published by Baishideng Publishing Group Inc. in World Journal of Diabetes
- Vol. 6 (3) , 391-402
Nociception at the diabetic foot, an uncharted territory
The diabetic foot is characterised by painless foot ulceration and/or arthropathy; it is a typical complication of painless diabetic neuropathy. Neuropathy depletes the foot skin of intraepidermal nerve fibre endings of the afferent A-delta and C-fibres, which are mostly nociceptors and excitable by noxious stimuli only. However, some of them are cold or warm receptors whose functions in diabetic neuropathy have frequently been reported. Hence, it is well established by quantitative sensory testing that thermal detection thresholds at the foot skin increase during the course of painless diabetic neuropathy. Pain perception (nociception), by contrast, has rarely been studied. Recent pilot studies of pinprick pain at plantar digital skinfolds showed that the perception threshold was always above the upper limit of measurement of 512 mN (equivalent to 51.2 g) at the diabetic foot. However, deep pressure pain perception threshold at musculus abductor hallucis was beyond 1400 kPa (equivalent to 14 kg; limit of measurement) only in every fifth case. These discrepancies of pain perception between forefoot and hindfoot, and between skin and muscle, demand further study. Measuring nociception at the feet in diabetes opens promising clinical perspectives. A critical nociception threshold may be quantified (probably corresponding to a critical number of intraepidermal nerve fibre endings), beyond which the individual risk of a diabetic foot rises appreciably. Staging of diabetic neuropathy according to nociception thresholds at the feet is highly desirable as guidance to an individualised injury prevention strategy.
- 1 January 2015
- Published by Baishideng Publishing Group Inc. in World Journal of Diabetes
- Vol. 6 (3) , 391-402
Open AccessNociception at the diabetic foot, an uncharted territory
The diabetic foot is characterised by painless foot ulceration and/or arthropathy; it is a typical complication of painless diabetic neuropathy. Neuropathy depletes the foot skin of intraepidermal nerve fibre endings of the afferent A-delta and C-fibres, which are mostly nociceptors and excitable by noxious stimuli only. However, some of them are cold or warm receptors whose functions in diabetic neuropathy have frequently been reported. Hence, it is well established by quantitative sensory testing that thermal detection thresholds at the foot skin increase during the course of painless diabetic neuropathy. Pain perception (nociception), by contrast, has rarely been studied. Recent pilot studies of pinprick pain at plantar digital skinfolds showed that the perception threshold was always above the upper limit of measurement of 512 mN (equivalent to 51.2 g) at the diabetic foot. However, deep pressure pain perception threshold at musculus abductor hallucis was beyond 1400 kPa (equivalent to 14 kg; limit of measurement) only in every fifth case. These discrepancies of pain perception between forefoot and hindfoot, and between skin and muscle, demand further study. Measuring nociception at the feet in diabetes opens promising clinical perspectives. A critical nociception threshold may be quantified (probably corresponding to a critical number of intraepidermal nerve fibre endings), beyond which the individual risk of a diabetic foot rises appreciably. Staging of diabetic neuropathy according to nociception thresholds at the feet is highly desirable as guidance to an individualised injury prevention strategy.
- Open Access
- 24 June 2014
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 8 (1) , 223
Insulin-induced localized lipoatrophy preceded by shingles (herpes zoster): a case report
Localized involutional lipoatrophy of subcutaneous adipose tissue may develop due to subcutaneous injection of pharmaceutical preparations. The pathogenesis of this adverse drug reaction is unknown. The progression of localized involutional lipoatrophy ceases and occasionally it resolves after withdrawing the inducing agent. In case of localized involutional lipoatrophy due to subcutaneous insulin therapy, low-dose systemic corticosteroids may be curative despite ongoing insulin administration. We report a recurrence of insulin-induced localized involutional lipoatrophy at the abdominal wall in a 57-year-old Caucasian woman with type-1 diabetes on continuous subcutaneous insulin infusion. The first episode of insulin-induced localized involutional lipoatrophy two years previously had been cured by oral prednisone. The recurrence was treated immediately with 10mg prednisone once daily for five months, and was cured thereafter. The insulin analog preparation (Humalog™) and the insulin pump equipment (Accu-Chek Spirit™) applied were the same during both episodes. Both episodes were preceded by a temporary disturbance of the immune balance (the first episode by vaccination, the second episode through shingles). This case confirms that insulin-induced localized involutional lipoatrophy in type-1 diabetes can occur again, and can be cured by systemic corticosteroids. We suggest that temporary disturbance of the immune balance may trigger this transitory idiosyncratic reaction in a susceptible individual.
- 24 June 2014
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 8 (1) , 223
Open AccessInsulin-induced localized lipoatrophy preceded by shingles (herpes zoster): a case report
Localized involutional lipoatrophy of subcutaneous adipose tissue may develop due to subcutaneous injection of pharmaceutical preparations. The pathogenesis of this adverse drug reaction is unknown. The progression of localized involutional lipoatrophy ceases and occasionally it resolves after withdrawing the inducing agent. In case of localized involutional lipoatrophy due to subcutaneous insulin therapy, low-dose systemic corticosteroids may be curative despite ongoing insulin administration. We report a recurrence of insulin-induced localized involutional lipoatrophy at the abdominal wall in a 57-year-old Caucasian woman with type-1 diabetes on continuous subcutaneous insulin infusion. The first episode of insulin-induced localized involutional lipoatrophy two years previously had been cured by oral prednisone. The recurrence was treated immediately with 10mg prednisone once daily for five months, and was cured thereafter. The insulin analog preparation (Humalog™) and the insulin pump equipment (Accu-Chek Spirit™) applied were the same during both episodes. Both episodes were preceded by a temporary disturbance of the immune balance (the first episode by vaccination, the second episode through shingles). This case confirms that insulin-induced localized involutional lipoatrophy in type-1 diabetes can occur again, and can be cured by systemic corticosteroids. We suggest that temporary disturbance of the immune balance may trigger this transitory idiosyncratic reaction in a susceptible individual.
- Open Access
- 20 April 2014
- Published by SMW Supporting Association in Swiss Medical Weekly
- Vol. 144 (1718) , w13948
Is the Eichenholtz classification still valid for the diabetic Charcot foot?
In his 1966 monograph “Charcot joints”, Sidney N. Eichenholtz (1909–2000) described “three well defined stages … in the course and development of a Charcot joint”, based on plain X-rays of 68 patients. Since then, medical imaging has advanced very much: computed tomography and magnetic resonance imaging (MRI) scans exceed plain X-ray by far in detecting foot fractures and other injuries. The earliest, nondeforming, X-ray-negative inflammatory stage of the acute Charcot joint of the diabetic foot can be visualised only by use of MRI. This stage, which Eichenholtz evidently failed to recognise, will heal without significant arthropathy, if treated in time. By contrast, the stages considered by Eichenholtz inevitably result in major arthropathy and foot deformity. Hence, superseding the Eichenholtz classification is overdue. We propose an MRI-based classification comprising two severity grades (0 and 1, according to absence/presence of cortical fractures) and two stages (active/inactive, according to presence/absence of skeletal inflammation).
- 20 April 2014
- Published by SMW Supporting Association in Swiss Medical Weekly
- Vol. 144 (1718) , w13948
Open AccessIs the Eichenholtz classification still valid for the diabetic Charcot foot?
In his 1966 monograph “Charcot joints”, Sidney N. Eichenholtz (1909–2000) described “three well defined stages … in the course and development of a Charcot joint”, based on plain X-rays of 68 patients. Since then, medical imaging has advanced very much: computed tomography and magnetic resonance imaging (MRI) scans exceed plain X-ray by far in detecting foot fractures and other injuries. The earliest, nondeforming, X-ray-negative inflammatory stage of the acute Charcot joint of the diabetic foot can be visualised only by use of MRI. This stage, which Eichenholtz evidently failed to recognise, will heal without significant arthropathy, if treated in time. By contrast, the stages considered by Eichenholtz inevitably result in major arthropathy and foot deformity. Hence, superseding the Eichenholtz classification is overdue. We propose an MRI-based classification comprising two severity grades (0 and 1, according to absence/presence of cortical fractures) and two stages (active/inactive, according to presence/absence of skeletal inflammation).
- Open Access
- 1 January 2014
- Published by Taylor & Francis in Diabetic Foot & Ankle
- Vol. 5 (1) , 24926
Effect of painless diabetic neuropathy on pressure pain hypersensitivity (hyperalgesia) after acute foot trauma
Effect of painless diabetic neuropathy on pressure pain hypersensitivity (hyperalgesia) after acute foot trauma
- 1 January 2014
- Published by Taylor & Francis in Diabetic Foot & Ankle
- Vol. 5 (1) , 24926
Open AccessEffect of painless diabetic neuropathy on pressure pain hypersensitivity (hyperalgesia) after acute foot trauma
Effect of painless diabetic neuropathy on pressure pain hypersensitivity (hyperalgesia) after acute foot trauma